Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis.

Dermatology and therapy·2026
Same author

Assessment of Sexual Behaviour Among HIV-Syphilis Coinfected Individuals From Designated Sexually Transmitted Infection/Reproductive Tract Infection (STI/RTI) Clinics in Mumbai, India.

Cureus·2026
Same author

In Vitro Reaction Phenotyping and Projection of Drug Interactions Mediated by Cytochrome P450 Enzymes for Central Nervous System Drugs as Victims: Implications for Safety in Vulnerable Populations.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Comparison of choroidal biomarkers and scleral thickness in keratoconus in relation to corneal cross-linking.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

A Conceptual Disease Model of Symptoms and Impacts in Adults with Prurigo Nodularis: A Qualitative and Literature-Informed Study.

Dermatology and therapy·2026
Same author

Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 drug evaluation.

Expert opinion on investigational drugs·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Vijay Benade1, Anil Shinde1, Rajesh Kumar Badange1

  • 1Suven Life Sciences Ltd, Hyderabad, Telangana, India.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

SUVN-I6107, a novel muscarinic M1 Positive Allosteric Modulator (PAM), demonstrated memory-enhancing effects in animal models of cognitive deficits. Further research is ongoing to evaluate its safety and efficacy in human subjects for dementia treatment.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • SUVN-I6107 is a novel muscarinic M1 Positive Allosteric Modulator (PAM) under development for treating dementia associated with neurodegenerative disorders.
  • This research investigated the pharmacological profile of SUVN-I6107 in preclinical models of cognitive impairment.

Purpose of the Study:

  • To characterize the selectivity and potency of SUVN-I6107 at muscarinic receptors.
  • To evaluate the effects of SUVN-I6107 on neuronal activity and cognitive function in animal models.
  • To assess the pharmacokinetic properties and brain penetration of SUVN-I6107.

Main Methods:

  • In vitro assays (calcium mobilization) were used to determine M1 receptor selectivity and potency.
  • Electrophysiology in hippocampal slices assessed SUVN-I6107's impact on neuronal firing.
  • Animal studies involved pharmacokinetic assessments, object recognition tasks (ORT), social recognition tasks (SRT), and measurement of neuronal markers (sAPPα, IP-1).

Main Results:

  • SUVN-I6107 exhibited allosteric potency at the M1 receptor and enhanced neuronal firing.
  • The compound demonstrated good oral bioavailability, brain penetration, and adequate protein-free fraction in preclinical species.
  • SUVN-I6107 reversed amnesia in ORT and improved memory in SRT and fear conditioning tasks, alongside increasing sAPPα and IP-1 levels.

Conclusions:

  • Non-clinical data suggest SUVN-I6107 possesses memory-enhancing properties beneficial for dementia treatment.
  • A Phase-1 clinical study (NCT06705088) is underway to assess SUVN-I6107's safety, tolerability, and pharmacodynamics in humans.